Efficacy of a two-dose hepatitis B vaccination with a novel immunostimulatory sequence adjuvant (Heplisav-B) on patients with chronic liver disease: a retrospective study

BACKGROUND: Patients with chronic liver disease (CLD) are more likely to have severe morbidity and mortality due to superimposed acute or chronic hepatitis B virus (HBV) infection and should receive routine vaccination against the virus. Heplisav-B is a two-dose, inactivated, yeast-derived vaccine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Joshua Y., Daoud, Nader, Ghoz, Hassan, Yataco, Maria L., Farraye, Francis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813651/
https://www.ncbi.nlm.nih.gov/pubmed/36704654
http://dx.doi.org/10.21037/tgh-22-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813651/
https://www.ncbi.nlm.nih.gov/pubmed/36704654
http://dx.doi.org/10.21037/tgh-22-12

Ejemplares similares